secwatch.observer — SEC 8-K summary
======================================

Issuer:     Rallybio Corp (RLYB)
CIK:        0001739410
Form:       8-K
Filed at:   2022-11-07T23:59:59+00:00
Accession:  0000950170-22-022335
Event type: earnings
Sentiment:  positive
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Rallybio Q3 net loss widens to $18.4M; positive RLYB116 Phase 1 data with >99% C5 reduction
--------------------------------------------------------------------------------

- Net loss $18.4M for Q3 2022, vs $10.2M for Q3 2021; net loss per share $0.60.
- Cash, cash equivalents, and marketable securities $132.4M as of Sep 30, 2022; runway into Q1 2024.
- RLYB212 Phase 1b shows rapid elimination of transfused platelets; proof-of-concept data expected Q1 2023.
- RLYB116 Phase 1: >99% reduction in free C5 within 24 hrs at 100 mg SC; half-life >300 hrs; MAD study in Q1 2023.
- R&D expenses $12.1M (up 142% YoY) driven by RLYB212 and RLYB116 development.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1739410/000095017022022335/0000950170-22-022335-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1739410/000095017022022335/rlyb-20221107.htm
  HTML page:      https://secwatch.observer/filing/0000950170-22-022335

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer